Buy and Bill Process Will Continue to Diminish in 2018! The term “Buy and Bill” refers to the process of physician management of certain medicines, primarily specialty medicines or drugs that require injection or infusion.
Buy and Bill has been the primary method of distribution of specialty drugs, primarily IV oncology drugs, whereby oncology practices typically purchase these drugs from specialty distributors/group purchasing organizations (GPOs), which are then billed to payers under the medical benefit.
Payers make reimbursement decisions during traditional buy and bill that go to the physician’s office. In the traditional buy and bill process, relationships with the pharmaceutical manufacturer, drug wholesaler and GPO impact the price the product purchase at the amount that the product is billed.
Recently, however, specialty pharmacies are making strong inroads into the buy and bill model via ‘white bagging’. White bagging is the method of delivery by which physician-administered drugs are dispensed by a specialty pharmacy (SP) for a specific patient, shipped to the physician for administration, and generally paid under the pharmacy benefit rather than the medical benefit. The payer for the drug reimburses the specialty pharmacy; the physician is only paid a drug administration fee.
Buy and Bill use is constantly changing and, as previously used by physicians, is still an option but all signs and trends indicate that its use will continue to diminish due to benefit design changes, ACA implementation with risk corridors, contracts among local and regional, rather than national stakeholders, and the increase in risk-sharing arrangements.
One of the main reasons for the confusion in understanding the use of Buy and Bill trend is that the data being reported often lags behind and doesn’t reflect the newer risk-based reimbursement agreements which are growing with hospital or individual providers.
AMI’s new report “Buy and Bill Process Will Continue to Diminish in 2018” identifies the critical issues facing pharmaceutical manufacturers and providers and offers strategies to work with Employers for success in the evolving market.
The report’s Table of Contents includes:
Cancer in the U.S – pgs. 5-7
Oncology – pgs. 8-12
Medicare Part B – pg. 13
Buy and Bill – pgs. 14-22
- White/Brown Bagging
Employers Role/Impact in Buy and Bill – pgs. 23-25
Conclusion – pgs. 26-27
References – pgs. 28-29
The report’s Tables and Figures includes:
- Estimated Number of New Cancer Cases in U.S. in 2018
- Percentage of Personalized Medicines Approved by the FDA
- Percent of Chemotherapy Drug Administration Claims in the Hospital Outpatient Setting
- Oral Drug Distribution Channels
- Percentage of Oncology Drugs Distributed Through Various Channels
- Components and Relationships with “Traditional” Distribution and Reimbursement Buy and Bill Mechanisms
- Basis for Physician Reimbursement Under Buy and Bill for Cancer Type Drugs
- Share of In-Practice Administered Drugs Purchased in 2015 by Source
- Oncology Practices Sourcing Some or All Drugs Through Specialty Pharmacies
- Components and Relationships with “Updated” Distribution and Reimbursement Buy and Bill Mechanisms
- Ratings by Employers of their Understanding About How Cancer Care Affects the Workforce
- Top 10 Health Conditions Costing Employers the Most